Monoclonal antibody or Antibody fragment thereof which competes with an Antibody selected from (a) to (c) below to recognize specifically the folr1 and binds to a HumanThe folr1 identical epitope epitope on the Human who joins the Antibody found in positions 55 to 62 in the amino acid sequence of Human folr1 represented by the SEC ID no. 1And it also shows an Antitumor Activity: (a) an Antibody in the complementarity determining Regions (referred to hereafter as CDR) 1 to 3 of heavy chain(referred to hereafter as h chain Antibody) comprising the Amino Acid Sequence represented by the SEC ID no. 30, 31 and 32, respectively,And the light chain CDR 1 to 3 (referred to hereafter as l chain Antibody) comprising the Amino Acid Sequence represented by the SEC ID no. 33, 34 and 35.Respectively (b) an Antibody in the COR 1 to 3 h chain Antibody comprising the Amino Acid Sequence represented by the SEC ID no. 30, 31 and 32, respectively,And the COR 1 to 3 l chain Antibody comprising the Amino Acid Sequence represented by the SEC ID no. 33, 34 and 35, respectively.And cysteine in the Amino Acid Sequence represented by the SEC ID no. 32 (The H Chain CDr3 Antibody) is replaced by threonine, methionine, isoleucine, Valine, phenylalanine, glutamine,The Antibody and (c) an Antibody in the H chain Antibody comprises the Amino Acid Sequence represented by the SEC ID no. 98 and the l chain Antibody comprises the seqSources of amino acids represented by the SEC ID no. 94.Anticuerpo monoclonal o fragmento de anticuerpo del mismo que compite con un anticuerpo seleccionado de entre los (a) a (c) siguientes para reconocer específicamente el FOLR1 humano y que se une a un epítopo idéntico al epítopo sobre el FOLR1 humano al que se une el anticuerpo que se encuentra en las posiciones 55 a 62 en la secuencia de aminoácidos de FOLR1 humano representada por la SEC ID nº 1 y que muestra asimismo una actividad antitumoral: (a) un anticuerpo en el que las regiones determinantes de complementarieda
